PALLAS Laser for Skin Diseases

NCT07250997 | Recruiting

• 2 other identifiers: MD-PALL-01CIV-HU-25-08-053914
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis). The secondary objective is to assess how user-friendly is the Pallas laser in the treatment of skin diseases. The patient in the trial will receive UVB laser treatment (2 treatments per week for up to 3 months). The treatments will be carried out by the doctors participating in the trial. The treatment takes approximately 10 minutes per session, and can last up to 3 months per patient. Photographic documentation of the lesions to be treated and the lesions treated is taken at the start of the examination and then once a month. At the end of the study, the patient rates the treatment and improvement on a Patient Satisfaction Scale.

Conditions

Psoriasis; Alopecia Areata; Atopic Dermatitis; Vitiligo Vulgaris

Keywords

UVB laser treatment; PALLAS laser; vitiligo; psoriasis; alopecia areata; atopic dermatitis

Outcome Measures

Primary Outcomes (1)

• Primary Endpoint: visible improvement of the treated skin disease.

  Vitiligo (VES score): https://www.vitiligo-calculator.com/ Psoriasis (PASI-score): https://pasi.corti.li/ Alopecia areata (SALT score) https://dermatopics.dk/salt-score/ Atopiás dermatitis (EASI score): https://www.easiderm.com/

  maximum 3 months

Secondary Outcomes (1)

• Dermatology Life Quality Index (DLQI)

  Maximum 3 months

Other Outcomes (1)

• Patient Satisfaction Score

  maximum 3 months

Study Arms (1)

Pallas Laser treated

OTHER

UVB treated patients

Device: UVB laser treatment

Interventions

UVB laser treatment DEVICE

In clinical practice, 311 nm ultraviolet B (UVB) phototherapy is often used to treat various skin conditions. In 1996, the 308 nm xenon chloride excimer laser was developed for the treatment of psoriasis. In the last decades, excimer treatment has been incorporated into international therapeutic protocols for the treatment of psoriasis alongside conventional 311 nm UVB therapies. In the present study, the investigators aim to gain experience with a UVB laser (Pallas) operating at a wavelength of 311 nm. The CE-marked Pallas UVB laser will be used for the same indications as the 308 nm excimer laser. The procedure is not new, but the significance of this study lies in its potential to provide us with experience using this device for targeted UVB treatment.

Pallas Laser treated

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The subject understands the information provided, gives informed consent to participate in the study and is deemed by the investigator to be able to participate,
• a skin condition that is expected to respond well to targeted UVB treatment,
• a signed consent form.

You may not qualify if:

• Patient under 18 years of age,
• pregnancy
• epilepsy,
• fever, infectious diseases,
• the patient is within one month or currently enrolled in another clinical trial.

Sponsors & Collaborators

• Szeged University: lead

Study Sites (1)

University of Szeged, Albert Szent-Györgyi Clinical Centre, Department of Dermatology and Allergology

Szeged, Csongrád-Csanád Vármegye, 6720, Hungary

RECRUITING

Related Publications (3)

• Baltas E, Csoma Z, Ignacz F, Dobozy A, Kemeny L. Treatment of vitiligo with the 308-nm xenon chloride excimer laser. Arch Dermatol. 2002 Dec;138(12):1619-20. No abstract available.

  PMID: 12472364 BACKGROUND

• Bonis B, Kemeny L, Dobozy A, Bor Z, Szabo G, Ignacz F. 308 nm UVB excimer laser for psoriasis. Lancet. 1997 Nov 22;350(9090):1522. doi: 10.1016/S0140-6736(05)63945-1. No abstract available.

  PMID: 9388408 BACKGROUND

• Baltas E, Nagy P, Bonis B, Novak Z, Ignacz F, Szabo G, Bor Z, Dobozy A, Kemeny L. Repigmentation of localized vitiligo with the xenon chloride laser. Br J Dermatol. 2001 Jun;144(6):1266-7. doi: 10.1046/j.1365-2133.2001.04248.x. No abstract available.

  PMID: 11422057 BACKGROUND

MeSH Terms

Conditions

Vitiligo; Psoriasis; Alopecia Areata; Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Hypopigmentation; Pigmentation Disorders; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Papulosquamous; Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Central Study Contacts

Lajos Kemény, professor, MD, DSc, MHAS

CONTACT

+36305152884; kemeny.lajos@med.u-szeged.hu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, MD, DSc, MHAS

Study Record Dates

• First Submitted: September 23, 2025
• First Posted: November 26, 2025
• Study Start: December 10, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: February 6, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

HU (1)